Efficacy of Terbinafine Versus Itraconazole in the Treatment of Tinea Corporis
Keywords:
Terbinafine, Itaconazole, tinea corporis, topical treatment, body surface areaAbstract
Background: Tinea corporis, sometimes referred to as 'ringworm,' is a superficial illness caused by dermatophytes that affects the skin. Objective: To compare the efficacy of terbinafine versus Itraconazole in the treatment of tinea corporis. Methods: This Randomized Control Trail was conducted at Department of Dermatology, DHQ Hospital ,Sheikhupura, during the duration of July 2023 till December 2023. Total 50 cases (25 in both groups) with Tinea corporis were included. Then patients were randomly divided into two groups. In group A, patients were given terbinafine. In group B, patients were given itraconazole. Then, the patients were followed-up for 2, 4, 6 and 8 weeks. On each visit, patients were examined for complete resolution of tinea, by using total body surface area index and they were assessed for resolution of leions. All the data was recorded in proforma and then entered & analyzed through SPSS version 26. Results: In the terbinafine group, the mean age of the patients was 35.16 ± 8.76 years. In the itraconazole group, the mean age of the patients was 28.36 ± 10.65 years. In the terbinafine group, there were 15 (60%) males and 10 (40%) females. Whereas, in the itraconazole group, there were 8 (32%) males and 17 (68%) females. Moreover, in the terbinafine group, the baseline BSI score was 6.44 ± 3.19 and this score was reduced to 3.64 + 2.11 after 4 weeks of treatment. In this group the efficacy (complete cure within 4 weeks) was achieved in 6 (24%) cases. On the other hand, in the itraconazole group, the baseline BSI score was 7.20 ± 2.99, which was reduced to 1.75 + 0.50 after 4 weeks of treatment and the efficacy (complete cure within 4 weeks) was achieved in 13(52%) cases in this group. Conclusion: We found that itraconazole has better efficacy than terbinafine for tinea corporis. Thus in future, itraconazole can be a drug of choice for such cases.References
Hsu S, Le EH, Khoshevis MR. Differential diagno-sis of annular lesions. Am Fam Physician. 2001; 64(2):289-97.
Sahoo AK, Mahajan R. Management of tinea cor-poris, tinea cruris, and tinea pedis: A comprehen-sive review. Indian Dermatol Online J. 2016;7(2): 77.
Surendran K, Bhat RM, Boloor R, Nandakishore B, Sukumar D. A clinical and mycological study of dermatophytic infections. Indian Dermatol Online J. 2014;59(3):262.
Ebrahimi M, Zarrinfar H, Naseri A, Najafzadeh MJ, Fata A, Parian M, et al. Epidemiology of der-matophytosis in northeastern Iran; A subtropical region. Curr Med Mycol. 2019;5(2):16.
Gupta AK, Venkataraman M, Quinlan EM. New antifungal agents and new formulations against dermatophytes. Dermatophytes and Dermatophy-toses. 2021:433-71.
Leung A, Barankin B. An itchy, round rash on the back of an adolescent’s neck. Consult Pediatr. 2014;13:466-9.
Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas C, Sardana K, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):1-11.
Bhatia A, Kanish B, Badyal DK, Kate P, Chou-dhary S. Efficacy of oral terbinafine versus itraco-nazole in treatment of dermatophytic infection of skin–a prospective, randomized comparative stu-dy. Indian J Pharmacol. 2019;51(2):116.
Sharma P, Bhalla M, Thami GP, Chander J. Evalu-ation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the manage-ment of dermatophytosis. J Dermatolog Treat. 2019.
Singh A, Masih A, Khurana A, Singh PK, Gupta M, Hagen F, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61(7):477-84.
Singh SK, Subba N, Tilak R. Efficacy of Terbina-fine and Itraconazole in Different Doses and in Combination in the Treatment of Tinea Infection: A Randomized Controlled Parallel Group Open Labeled Trial with Clinico-Mycological Correlat-
ion. Indian Dermatol Online J. 2020;65(4):284-9.
Alter SJ, McDonald MB, Schloemer J, Simon R, Trevino J. Common child and adolescent cutane-ous infestations and fungal infections. Curr Probl Pediatr Adolesc Health Care. 2018;48(1):3-25.
Leung AK, Hon KL, Leong KF, Barankin B, Lam JM. Tinea capitis: an updated review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):58-68.
Nenoff P, Krüger C, Ginter?Hanselmayer G, Tietz HJ. Mycology–an update. Part 1: Dermatomyco-ses: causative agents, epidemiology and pathoge-nesis. JDDG: Journal der Deutschen Dermatologis-chen Gesellschaft. 2014;12(3):188-210.
Leung AK, Lam JM, Leong KF. Childhood solitary cutaneous mastocytoma: clinical manifestations, diagnosis, evaluation, and management. Current pediatric reviews. 2019;15(1):42-6.
Leung AK, Lam JM, Leong KF, Hon KL, Barankin B, Leung AA, et al. Onychomycosis: an updated review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):32-45.
Kakurai M, Harada K, Maeda T, Hiruma J, Kano R, Demitsu T. Case of tinea corporis due to terbi-nafine?resistant Trichophyton interdigitale. J Der-matol. 2020;47(4):e104-e5.
Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. Fungal Genet Biol. 2019; 132:103255.
Singh S, Shukla P. End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol. 2018;84:554.
Majid I, Sheikh G, Kanth F, Hakak R. Relapse after Oral Terbinafine Therapy in Dermatophytosis: A Clinical and Mycological Study. Indian J Derma-tol. 2016;61(5):529-33.
Singh S, Shukla P. End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol. 2018;84.
Bhatia A, Kanish B, Badyal DK, Kate P, Choud-hary S. Efficacy of oral terbinafine versus itracona-zole in treatment of dermatophytic infection of skin – A prospective, randomized comparative study. Indian J Pharmacol. 2019;51(2):116-9.
Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B. Efficacy and Safety of Terbina-fine 500 mg Once Daily in Patients with Dermato-phytosis. Indian J Dermatol. 2017;62(4):395-9.
El?Gohary M, van Zuuren EJ, Fedorowicz Z, Bur-gess H, Doney L, Stuart B, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014(8).
Sultana T, Saha S, Hossain M, Ajmeri S, Sarker M, Sultana M, et al. Current Trends of Using Systemic Antifungal Drugs and their Comparative Efficacy in Tinea Corporis and Tinea Cruris in Outpatient Department of Dermatology in a Tertiary Level Hospital. Mymensingh Med J. 2018;27(1):52-6.
Goldstein AO, Goldstein BG. Dermatophyte (tin-ea) infections. Walthman, MA: UpToDate. 2017.
